Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityNo recent work listed

Hengyue Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1847-4290; OpenAlex author ID A5080621604. Sources: OpenAlex.

Their work

Papers
10 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2020: 3 papers · 2021: 5 papers · 2022: 2 papers

Papers 10

  1. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress p… First author DOI 10.1038/s41419-022-04573-7↗
  2. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability an… First author DOI 10.1038/s41419-022-04705-z↗
  3. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Co-author DOI 10.1007/s10565-020-09562-0↗
  4. Correction to: Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. First author DOI 10.1186/s12906-021-03254-w↗
  5. NUDCD1 knockdown inhibits the proliferation, migration, and invasion of pancreatic cancer via the EMT process. Co-author DOI 10.18632/aging.203276↗
  6. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Co-author DOI 10.18632/aging.203301↗
  7. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Co-author DOI 10.18632/aging.203725↗
  8. Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. First author DOI 10.1186/s12906-020-02976-7↗
  9. The Anti-Dysenteric Drug Fraxetin Enhances Anti-Tumor Efficacy of Gemcitabine and Suppresses Pancreatic Cancer Development by Antagonizing STAT3 Activation Co-author DOI 10.21203/rs.3.rs-125318/v1↗
  10. CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. First author DOI 10.3389/fphar.2020.580407↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yangyang Guo · 10 shared papers, 2020–2022 · strength 1.38
  2. Yanyi Xiao · 6 shared papers, 2020–2022 · strength 0.79
  3. Hangcheng Guo · 6 shared papers, 2020–2022 · strength 0.79
  4. Yongheng Bai · 6 shared papers, 2020–2022 · strength 0.79
  5. Qiyu Zhang · 4 shared papers, 2020–2022 · strength 0.53
  6. Linxiao Sun · 3 shared papers, 2020–2021 · strength 0.45
  7. Cheng Wang · 3 shared papers, 2020–2021 · strength 0.45
  8. Miaomiao Lin · 2 shared papers, 2022 · strength 0.30
  9. Junjie Deng · 2 shared papers, 2020–2021 · strength 0.23
  10. Zhensheng Cao · 1 shared paper, 2021 · strength 0.14
  11. Chunling Shi · 1 shared paper, 2021 · strength 0.14
  12. Hewei Zhang · 1 shared paper, 2020 · strength 0.13
  13. Xiangyang Lin · 1 shared paper, 2021 · strength 0.13
  14. Yunfeng Shan · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.